NCT05408546Active, not recruitingPhase 2
Evaluation of the Safety and Thrombolytic Effects of Ascending Doses of TS23 in Subjects With Intermediate-Risk (Sub-Massive) Acute Pulmonary Embolism
Translational Sciences, Inc.13 sites in 1 country64 target enrollmentStarted: May 24, 2023Last updated:
Conditions
Interventions
Drugs
Trial Snapshot
- Phase
- Phase 2
- Status
- Active, not recruiting
- Sponsor
- Translational Sciences, Inc.
- Enrollment
- 64
- Locations
- 13
- Primary Endpoint
- Safety- Bleeding
Study Overview
Brief Summary
Phase II trial of TS23
Detailed Description
Evaluation of safety and thrombolytic effect of ascending doses of TS23 in subjects with intermediate-risk (sub-massive) acute pulmonary embolism (PE)
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Male or female subjects, age >18 years;
- •PE involving a segmental or more proximal pulmonary artery confirmed by CTPA scan and with an onset of symptoms not more than 5 days prior to diagnosis;
- •Subject is hemodynamically stable with a systolic blood pressure (SBP) >90 mm Hg;
- •Subject has evidence of RV dysfunction as indicated by a right ventricular-to-left ventricular (RV/LV) diameter ratio > 0.9 on CTPA scan (measuring the minor axis of the right and left ventricle in the transverse plane), prior to the initiation of study drug administration.
Exclusion Criteria
- •Subjects for whom thrombolytic therapy or thrombectomy is planned; or subjects with history of administration of thrombolytic agents within the previous 4 days;
- •Subjects receiving ≥ 48 hours of therapeutic doses of heparin or low molecular weight heparin (LMWH) or other anticoagulant therapy immediately prior to randomization;
- •Subjects with contraindications to SOC therapies such as unfractionated heparin or LMWH or oral anticoagulant, or any of the excipients (including study drug excipients);
- •Subjects who are considered at very high risk of bleeding:
- •Known coagulation disorder with history of pathologic bleeding tendencies
- •Subjects with prior intracranial hemorrhage, known arteriovenous malformation or aneurysm of the brain, or evidence of active bleeding;
- •Subjects with a history of major surgery, clinically significant head trauma (in the opinion of the Principal Investigator), or stroke in the past 3 months prior to randomization;
- •Subjects with uncontrolled hypertension defined as SBP ≥180 mm Hg and/or diastolic BP (DBP)
- •≥110 mm Hg at randomization
- •Subjects requiring concomitant dual antiplatelet therapy
- •Subjects with Creatinine Clearance (CrCL) < 30 mL/min or serum creatinine ≥ 2.5 mg/dL;
- •Subjects with hemoglobin < 8.0 g/dL;
- •Subjects with a platelet count < 100,000/µL;
- •Subjects with acute or persistent hepatitis or diagnosed active liver disease or with elevation of liver enzymes: Alanine transaminase (ALT) or aspartate transaminase (AST) ≥ 3 x upper limit of normal (ULN);
- •Subjects with known history of testing positive for Hepatitis B antigen or Hepatitis C antibody;
- •Subjects with known history of testing positive for the human immunodeficiency virus (HIV);
- •Subjects with life-expectancy < 6 months;
- •Female subjects of child bearing potential with a positive pregnancy test or who are lactating, or unwilling to use highly effective methods of contraception. Highly effective methods of birth control include combination hormonal therapy (estrogen and progresterone), contraceptives administered orally, intravaginally or transdermally, progesterone-only contraceptives administered orally, by injection or implantation, use of an intrauterine device (IUD), intrauterine hormone- releasing system (IUS), bilateral tubal occlusion, partner vasectomy or sexual abstinence;
- •Subjects currently participating in another investigational study or who have participated in an investigational drug study within 30 days (or longer depending on the half-life of the investigational drug; should allow at least five half-life of the investigational drug) prior to randomization.
Arms & Interventions
Higher dose TS23
Experimental
TS23 highest dose + SOC anticoagulation
Intervention: TS23 (Drug)
Intermediate dose TS23
Experimental
TS23 medium dose + SOC anticoagulation
Intervention: TS23 (Drug)
Placebo
Placebo Comparator
Placebo + standard of care (SOC) anticoagulation
Intervention: Placebo (Drug)
Low dose TS23
Experimental
TS23 low dose + SOC anticoagulation
Intervention: TS23 (Drug)
Outcomes
Primary Outcomes
Safety- Bleeding
Time Frame: within 7 days of treatment
Frequency of major or clinically significant bleeding
RV/LV
Time Frame: 48 hours after treatment
Ratio of the right to left ventricle dimensions on CT perfusion angiogram (CTPA)
Secondary Outcomes
- Thrombus dissolution(48 hours after treatment)
Investigators
Study Sites (13)
Loading locations...
Similar Trials
Completed
Phase 2
Pharmacokinetics, Efficacy and Safety Assessment of T2345 Compared With Active Comparator in Newly Diagnosed Patients With Open-angle Glaucoma or Ocular HypertensionPrimary Open Angle GlaucomaNCT01494753Laboratoires Thea30
Completed
Not Applicable
An International Observational Study of the Safety and Efficacy of Thrombolysis in StrokeStrokeNCT02229890Boehringer Ingelheim593
Completed
Phase 3
Avatrombopag for the Treatment of Thrombocytopenia in Pediatric Subjects With Immune Thrombocytopenia for ≥6 MonthsImmune ThrombocytopeniaNCT04516967Sobi, Inc.75
Completed
Phase 1
Clinical Study of TS-143 in Healthy Adult Male Subjects (Multiple-Dose Administration)Healthy ParticipantsNCT03595202Taisho Pharmaceutical Co., Ltd.24
Completed
Phase 1
Safety, Tolerability and Efficacy Study of TT-173 in Healthy Volunteers After Tooth ExtractionTooth ExtractionNCT01595360Thrombotargets Europe S.L24